Abstracts tagged "COVID-19"

Abstract Number: 076 • 2023 Pediatric Rheumatology Symposium
COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Brooke Rezmer¹, Michelle Adler², Tamar Rubinstein³, Andrea Knight⁴ and Natoshia Cunningham⁵, ¹Michigan State University College of Human Medicine, Grand Rapids, MI, ²Michigan State University, East Lansing, ³Children's Hospital at Montefiore, New York, NY, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Michigan State University, Grand Rapids, MI
Background/Purpose: Psychological symptoms are common in childhood-onset systemic lupus erythematosus (cSLE) and may impact other psychological and health-related outcomes. Mental health problems such as anxiety…
Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Rebecca Hetrick¹, Maria Pereira² and Marietta De Guzman³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
Abstract Number: 097 • 2023 Pediatric Rheumatology Symposium
Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease
Mariana Correia Marques¹, Paul Subrata², Carol Lake³, Ly-Lan Bergeron⁴, Rashmi Sinha⁵, Luciana Peixoto⁶, Marinka Twilt⁷ and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases/Children`s National Hospital, Bethesda, MD, ²NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³NIH, GAITHERSBURG, MD, ⁴NIH/NIAMS, Vienna, VA, ⁵Systemic JIA Foundation, Cincinnati, OH, ⁶Systemic JIA Foundation, Cincinnati, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD
Background/Purpose: Immunization is one of the most important tools for the control of the Covid-19 pandemic. The safety and effectiveness of the Covid-19 immunizations have…
Abstract Number: 099 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis
Tresa Ambooken¹, Sangati Kadakia¹, Tara Lozy¹, Brianna Bulbin², Suhas Ganguli³, Dawn Wahezi⁴ and Sivia Lapidus¹, ¹Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Hackensack Meridian School of Medicine, Hackensack, NJ, ³Department of Pediatrics, K. Hovnanian Children's Hospital, Jersey Shore University Medical Center, Neptune City, NJ, ⁴Children's Hospital at Montefiore, New York, NY
Background/Purpose: Juvenile Dermatomyositis (JDM) is theorized to occur in a genetically susceptible individual as a response to an environmental trigger, leading to autoimmunity and inflammation.…
Abstract Number: 105 • 2023 Pediatric Rheumatology Symposium
Awareness of Multisystem Inflammatory Syndrome in Children Among U.S. Parents: A Cross-Sectional Survey
Lyndsey Cole¹, E. Adrianne Hammershaimb², Yuanyuan Liang², Megan Hendrich³, Dhiman Das³, Robert Petrin³, James Campbell², Sean O'Leary¹ and Jessica Cataldi¹, ¹University of Colorado School of Medicine, Denver, CO, ²University of Maryland School of Medicine, Baltimore, MD, ³Ipsos US Public Affairs, Washington, DC
Background/Purpose: Little is known about parental awareness of multisystem inflammatory syndrome in children (MIS-C), a rare but severe sequela of SARS-CoV-2 infection. We sought to…
Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 117 • 2023 Pediatric Rheumatology Symposium
A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children
Alexis Begezda, Penn State, State College, PA
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…
Abstract Number: L08 • ACR Convergence 2022
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Christopher Podgorski¹ and Deborah Parks², ¹BJC/Washington University Consortium, St. Louis, MO, ²Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The…
Abstract Number: 0215 • ACR Convergence 2022
Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study
Mostafa Ahmad¹, Frances Parry² and Simon Maxwell², ¹Western General Hospital, Edinburgh, Scotland, United Kingdom, ²MSc Internal Medicine, University of Edinburgh, Edinburgh, Scotland, United Kingdom
Background/Purpose: Enhancing physical examination skills improves the identification of clinical findings, decision-making and overall management. Feedback is a crucial factor in achieving effective learning but…
Abstract Number: 0703 • ACR Convergence 2022
Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry
Jose A Gomez-Puerta¹, Ana Lúcia Martins Fernandes², Juan Camilo Sarmiento-Monroy¹, Saskia Lawson-Tovey³, Kimme Hyrich⁴, Laure Gossec⁵, Loreto Carmona⁶, Anja Strangfeld⁷, Elsa Mateus⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Marta Mosca¹¹, Patrick Durez¹², Bernd Raffeiner¹³, Nicolas Roux¹⁴, Viellard Eric¹⁵, Olivier Brocq¹⁶, Julija Zepa¹⁷, Eva Strakova¹⁸, Inita Bulina¹⁹, Vanda Mlynarikova²⁰, Emoke Šteňová²¹, Martin Soubrier²², Xavier Mariette²³ and Pedro Machado²⁴, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Centro Hospitalar Universitário do Algarve, Faro, Portugal, ³Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Sorbonne Université, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁸EULAR, Lisboa, Portugal, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹³Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ¹⁴Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ¹⁵Private practice, St. Malo, France, ¹⁶Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹⁷Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ¹⁸Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ¹⁹Pauls Stradins Clinical University Hospital, Riga, Riga, Latvia, ²⁰National Institute of Rheumatic Diseases, Piešťany, Slovakia, ²¹University Hospital, Bratislava, Slovakia, ²²Gabriel-Montpied Hospital, Clermont-Ferrand, France, ²³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁴University College London, London, United Kingdom
Background/Purpose: Some concerns have been raised with the use of vaccines against SARS-CoV-2 in patients with Systemic Autoimmune Diseases (SAD) including the risk of serious…
Abstract Number: 0772 • ACR Convergence 2022
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Carina Soto-Fajardo¹, Angélica Peña Ayala², Fernanda Gonzalez², Paola Flores², Ana Cristina Medina², Araceli Bernal², Carlos Pineda², Olga-Lidia Vera-Lastra³ and Luis Javier Jara Quezada², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Centro Médico La Raza, Ciudad de México, Mexico
Background/Purpose: From January 2021 around 60% of the total population has received at least one dose of any COVID-19 vaccine. A minority of vaccinated individuals…
Abstract Number: 0793 • ACR Convergence 2022
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Norman Gaylis¹, Odense DeLaRosa¹, Nayak Polissar², Nirnaya Miljacic² and Andrew Holman³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Mountain Whisper Light, Seattle, WA, ³Inmedix Inc, Seattle, WA
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with SARS-CoV-2 develop post-COVID symptoms. (1) This has been defined by the…
Abstract Number: 0950 • ACR Convergence 2022
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
Sinead Maguire¹, Samar Al emadi², Paul Alba³, Mathia C Aguiar⁴, Talal Al Lawati⁵, Gelsomina Alle⁶, Bonnie Bermas⁷, Suleman Bhana⁸, Branimir Anic⁹, Inita Bulina¹⁰, Megan Clowse¹¹, Adriana Karina Cogo¹², Iris Colunga¹³, Claire Cook¹⁴, KAREN JOYCE CORTEZ¹⁵, Kathryn Dao¹⁶, Milena Gianfrancesco¹⁷, Monique Gore-Massy¹⁸, Laure Gossec¹⁹, Rebecca Grainger²⁰, Jonathan Hausmann²¹, Tiffany YT Hsu²², Kimme Hyrich²³, Carolina Isnardi²⁴, Yumeko Kawano²², Rachael Kilding²⁵, Daria A Kusevich²⁶, Saskia Lawson-Tovey²⁷, Jean Liew²⁸, Eoghan McCarthy²⁹, Anna Montgomery³⁰, Sebastian Moyano³, Noreen Nasir³¹, IVAN PADJEN³², Charalampos Papagoras³³, Naomi Patel³⁴, MARIANA PERA³⁵, Cecilia Pisoni³⁶, Guillermo Pons-Estel³⁷, Antonio Lorenzo Quiambao³⁸, Rosana Quintana³⁹, Eric Ruderman⁴⁰, Sebastian Sattui⁴¹, Veronica Savio⁴², Savino Sciascia⁴³, Marieta Sencarova⁴⁴, Rosa Serrano-Morales⁴⁵, Faizah Siddique⁴⁶, Emily Sirotich⁴⁷, Jeffrey Sparks⁴⁸, Anja Strangfeld⁴⁹, Paul Sufka⁵⁰, Helen Tanner⁵¹, Yohana Tissera⁵², Zachary Wallace¹⁴, Marina Werner⁵³, Leanna Wise⁵⁴, Angus Worthing⁵⁵, JoAnn Zell⁵⁶, Julija Zepa¹⁰, Pedro Machado⁵⁷, Jinoos Yazdany¹⁷, Philip Robinson⁵¹ and Richard Conway¹,¹St James' Hospital, Dublin, Ireland, ²Hamad Medical Corporation, Doha, Qatar, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital General Agustin O`Horan, Merida, Mexico, ⁵Sultan Qaboos University Hospital, Muscat, Oman, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷UT Southwestern, Dallas, TX, ⁸Crystal Run Healthcare, Middletown, NY, ⁹Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, ¹⁰Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, ¹¹Duke University, Durham, NC, ¹²Hospital Interzonal Luis Guemes, Haedo and Hospital San Juan de Dios, Castelar, Buenos Aires, Argentina, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Massachusetts General Hospital, Boston, MA, ¹⁵Baguio General Hospital Medical Center, Baguio, Philippines, ¹⁶UT Southwestern Medical Center, Dallas, TX, ¹⁷University of California San Francisco, San Francisco, CA, ¹⁸Covid-19 GRA, West Orange, NJ, ¹⁹Sorbonne Université, Paris, France, ²⁰University of Otago, Wellington, New Zealand, ²¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²²Brigham and Women's Hospital, Boston, MA, ²³The University of Manchester, Manchester, United Kingdom, ²⁴SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁵Sheffield teaching hospitals trust, Sheffield, United Kingdom, ²⁶VA Nasonova Research Institute of Rheumatology, Moscow and Anikina Clinic, Vidnoe, Russia, ²⁷Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²⁸Boston University, Boston, MA, ²⁹Beaumont Hospital, Dublin, Ireland, ³⁰University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³¹Aga Khan University Hospital, Karachi Pakistan, Karachi, Pakistan, ³²University Hospital Center Zagreb, Zagreb, Croatia, ³³First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ³⁴Massachusetts General Hospital, Sale Creek, TN, ³⁵Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, ³⁶CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ³⁸East Avenue Medical Center, Quezon City, Philippines, ³⁹Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁴⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴¹University of Pittsburg, Pittsburg, Pennsylvania, USA, PIttsburgh, PA, ⁴²Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, ⁴³University of Turin, Torino, Italy, ⁴⁴Univerzitna nemocnica L Pasteura, Slovakia, Kosice, Slovakia, ⁴⁵Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, ⁴⁶Loyola University Medical Center, Elmhurst, IL, ⁴⁷Department of Health Research, Evidence and Impact, McMaster University, Hamilton, ON, Canada, ⁴⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁵⁰HealthPartners, Eagan, MN,⁵¹University of Queensland School of Medicine, Brisbane, Queensland, Australia, ⁵²Internal Medicine Service, Rheumatology Unit, Hospital Córdoba y Sanatorio Parque de Córdoba, Córdoba, Argentina, ⁵³Hospital Nacional de Clínicas, Córdoba, Argentina, ⁵⁴LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁵⁵Arthritis & Rheumatism Associates, PC, Washington, DC, ⁵⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London and National Institute for Health Research (NIHR), University College London Hospitals NHS Foundation Trust, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
Background/Purpose: To describe obstetric outcomes based on COVID-19 vaccination status in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.Methods: We extracted…
Abstract Number: 1330 • ACR Convergence 2022
Impact of COVID-19 Severity on Physical Function, Mobility, Falls and Fractures Among Older Patients After Hospitalization: A Longitudinal Study
Clara Wong¹, Diego Cabrera², Mary Geda³, Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh², ¹Yale School of Public Health, New Haven, CT, ²Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: No longitudinal studies have examined the impact of COVID-19 or COVID-19 severity on physical function and disability outcomes among older adults. Multiple factors, including…
Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Angie El-Said¹, Areeb Ahmad², Massimo Valenti³, Neel K. Shah¹, Susana Soto¹ and Shazia Beg⁴, ¹University of Central Florida College of Medicine, Orlando, FL, ²University of Central Florida, Orlando, FL, ³Sapienza University of Rome, School of Medicine, Rome, Italy, ⁴UCF, Orlando, FL
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].